On November 16, 2023, Nature's Toolbox (NTx), a life sciences company building next generation platforms to manufacture RNA and protein, announced the close of a $47.5 million Series B funding round led by RA Capital Management, with strong participation from existing investors Anzu Partners and BlueStone Venture Partners. Wilson Sonsini Goodrich & Rosati advised NTx on the transaction.

The fundraise will enable NTx to continue to advance its biomanufacturing platforms, NTxscribe® and NTxpress®. Acceleration of these technology foundations will enable distribution of manufacturing capabilities globally, ultimately providing solutions to prepare for future pandemic events, personalized medicine therapy, and increased access to critical vaccines and medicines.

The Wilson Sonsini team that advised NTx on the transaction includes:

Corporate
Mark Solakian
Jake Gatof
Kristen Kercher
Priyanka Nawathe
Reilly Clark
Tamara Labanowski
Erica Wolfe Heinz
Rebecca Lilley

Delaware Law
Ryan Greecher
James Griffin-Stanco
Allurie Kephart
Ryan Hart

Tax
Gregory Broome
Anjali Krishnan

Employee Benefits and Compensation
Matthew Norgard

For more information, please see NTx's news release. Additional coverage can be found on EndPoints News, Fierce Pharma, and New Mexico Inno.